Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix

Zohydro in March was blocked by regulators in the state of Massachusetts.

On Monday, however, Zohydro was included back onto the MassHealth drug list, with “prior authorization." According to Masshealth, "The updates to the List are effective immediately, unless otherwise specified. For medications that have new PA requirements."

Zogenix (NASDAQ: ZGNX), moved higher by 11.1 percent in Tuesdays pre-market trading session, but he optimism faded in Tuesday's trading session.

Difei Yang from R.F. Lafferty & Co stated, "The impact from Massachusetts approval of Zohydro won't add much in terms of incremental revenue for Zygonex. The Massachusetts approval was a minor catalyst."

Zogenix traded recently at $1.33, down 0.75 percent.